Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Domenico D'AtriLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2584-984X
Elena TondiniExperimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Federico MachinandiarenaLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-3149-9951
Minsuk KongLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6876-4520
Alilin MiaLaboratory Animal Sciences Program, Leidos Biomedical Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Devorah GallardoLaboratory Animal Sciences Program, Leidos Biomedical Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kandice TannerLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stephen M HewittLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
David J FitzgeraldLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6589-0126
Kumaran S RamamurthiLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2335-3568
Funding
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
Peptide-based therapeutic immunizations represent safe approaches to elicit antigen-specific T cell responses, but their broad utility remains limited due to poor immunogenicity and short
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growth. · full record | OpenQuestion